<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7196187\results\search\disease\results.xml">
  <result pre="been taken by the government to control and prevent the" exact="Severe" post="Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). This pandemic situation"/>
  <result pre="taken by the government to control and prevent the Severe" exact="Acute" post="Respiratory Syndrome coronavirus 2 (SARS-CoV-2). This pandemic situation has"/>
  <result pre="by the government to control and prevent the Severe Acute" exact="Respiratory" post="Syndrome coronavirus 2 (SARS-CoV-2). This pandemic situation has forced"/>
  <result pre="the government to control and prevent the Severe Acute Respiratory" exact="Syndrome" post="coronavirus 2 (SARS-CoV-2). This pandemic situation has forced scientists"/>
  <result pre="pandemic situation has forced scientists to rework strategies to combat" exact="infectious diseases" post="through drugs, treatment, and control measures. COVID-19 treatment requires"/>
  <result pre="drugs, treatment, and control measures. COVID-19 treatment requires both limiting" exact="viral" post="multiplication and neutralizing tissue damage induced by an inappropriate"/>
  <result pre="specimens/samples, recent efficient diagnostics, and therapeutic approaches to control the" exact="disease" post="and repurposed drugs mainly focusing on chloroquine/hydroxychloroquine and convalescent"/>
  <result pre="plasma (CP) COVID-19 Current diagnostics SARS-CoV-2 INTRODUCTION The novel coronavirus" exact="disease" post="2019 (COVID-19), an outbreak caused by the Severe Acute"/>
  <result pre="novel coronavirus disease 2019 (COVID-19), an outbreak caused by the" exact="Severe" post="Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), continues to spread,"/>
  <result pre="coronavirus disease 2019 (COVID-19), an outbreak caused by the Severe" exact="Acute" post="Respiratory Syndrome coronavirus 2 (SARS-CoV-2), continues to spread, and"/>
  <result pre="disease 2019 (COVID-19), an outbreak caused by the Severe Acute" exact="Respiratory" post="Syndrome coronavirus 2 (SARS-CoV-2), continues to spread, and as"/>
  <result pre="2019 (COVID-19), an outbreak caused by the Severe Acute Respiratory" exact="Syndrome" post="coronavirus 2 (SARS-CoV-2), continues to spread, and as per"/>
  <result pre="of COVID-19 is more severe than that of the previous" exact="Severe" post="Acute Respiratory Syndrome (SARS) and the Middle East Respiratory"/>
  <result pre="COVID-19 is more severe than that of the previous Severe" exact="Acute" post="Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome"/>
  <result pre="is more severe than that of the previous Severe Acute" exact="Respiratory" post="Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS),"/>
  <result pre="more severe than that of the previous Severe Acute Respiratory" exact="Syndrome" post="(SARS) and the Middle East Respiratory Syndrome (MERS), because"/>
  <result pre="previous Severe Acute Respiratory Syndrome (SARS) and the Middle East" exact="Respiratory" post="Syndrome (MERS), because of the increased industrialization, which led"/>
  <result pre="Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory" exact="Syndrome" post="(MERS), because of the increased industrialization, which led to"/>
  <result pre="third coronavirus epidemic after the SARS and MERS coronavirus outbreaks." exact="Structural" post="studies revealed that there is a close relationship between"/>
  <result pre="and SARS-CoV. SARS-CoV-2, which causes COVID-19, is spherical, and the" exact="viral" post="envelope entails a bilipid layer, which has the membrane"/>
  <result pre="ACE2 receptors, leading to COVID-19 related pneumonia, while also causing" exact="acute" post="myocardial injury and chronic damage to the cardiovascular system"/>
  <result pre="COVID-19 related pneumonia, while also causing acute myocardial injury and" exact="chronic" post="damage to the cardiovascular system (3). The transmission of"/>
  <result pre="also causing acute myocardial injury and chronic damage to the" exact="cardiovascular" post="system (3). The transmission of COVID-19 is primarily caused"/>
  <result pre="is primarily caused by human coming into contact with the" exact="viral" post="droplets, which suggests that keeping a one-meter distance from"/>
  <result pre="COVID-19 pandemic has forced scientists to rework strategies to combat" exact="infectious diseases" post="through drugs, treatment, and control measures. The entire world"/>
  <result pre="institutions. The South Korean government and the Korean Centers for" exact="Disease" post="Control and Prevention (KCDC) have announced urgent research projects"/>
  <result pre="ensure that people are well prepared to conquer this deadly" exact="infection" post="of COVID-19. The government of India has announced the"/>
  <result pre="light of this, it will become increasingly necessary to maintain" exact="systemic" post="and coordinated efforts between the public, clinical, commercial, and"/>
  <result pre="cases of COVID-19 may be presented with either asymptomatic or" exact="symptomatic" post="infection, which could range from mild to severe or"/>
  <result pre="infection, which could range from mild to severe or life-threatening" exact="pneumonia" post="(5). Particularly, COVID-19 seems to be transmitted mostly during"/>
  <result pre="mild non-specific symptoms (6). The common symptoms associated with this" exact="disease" post="are high fever, cough, difficulty in breathing, and lesions"/>
  <result pre="lungs; in the worst cases, it can cause severe pneumonia," exact="acute" post="respiratory distress syndrome (ARDS), and risk for life (7)."/>
  <result pre="in the worst cases, it can cause severe pneumonia, acute" exact="respiratory" post="distress syndrome (ARDS), and risk for life (7). Individuals"/>
  <result pre="worst cases, it can cause severe pneumonia, acute respiratory distress" exact="syndrome" post="(ARDS), and risk for life (7). Individuals affected with"/>
  <result pre="of their family as well as society. The Centre for" exact="Disease" post="Control and Prevention (CDC) (8), the World Health Organization"/>
  <result pre="will be isolated from two major sources, which are the" exact="lower" post="respiratory tract and the upper respiratory tract. The specimens,"/>
  <result pre="be isolated from two major sources, which are the lower" exact="respiratory" post="tract and the upper respiratory tract. The specimens, such"/>
  <result pre="major sources, which are the lower respiratory tract and the" exact="upper" post="respiratory tract. The specimens, such as a nasopharyngeal swab"/>
  <result pre="sources, which are the lower respiratory tract and the upper" exact="respiratory" post="tract. The specimens, such as a nasopharyngeal swab (NP)"/>
  <result pre="or the oropharyngeal swab (OP), will be collected from the" exact="upper" post="respiratory tract, whereas the bronchoalveolar lavage, tracheal aspirate, or"/>
  <result pre="the oropharyngeal swab (OP), will be collected from the upper" exact="respiratory" post="tract, whereas the bronchoalveolar lavage, tracheal aspirate, or sputum"/>
  <result pre="lavage, tracheal aspirate, or sputum will be collected from the" exact="lower" post="respiratory tract (Table 1). Nasopharyngeal swabs: The NP specimen"/>
  <result pre="tracheal aspirate, or sputum will be collected from the lower" exact="respiratory" post="tract (Table 1). Nasopharyngeal swabs: The NP specimen is"/>
  <result pre="a 2-3 mL of sterile medium or saline for proper" exact="viral" post="transport. If the NP swabs are not available, then"/>
  <result pre="nares and mid-turbinate specimen can also be collected from the" exact="symptomatic" post="patients for the detection of the viral infection. Oropharyngeal"/>
  <result pre="collected from the symptomatic patients for the detection of the" exact="viral infection." post="Oropharyngeal swabs: Another important specimen recommended by the WHO"/>
  <result pre="specimen recommended by the WHO and CDC to detect SARS-CoV-2" exact="infection" post="is the OP. This swab is collected from the"/>
  <result pre="infection is the OP. This swab is collected from the" exact="posterior" post="pharynx region, avoiding contact with the tongue. According to"/>
  <result pre="lavage (BAL) and tracheal aspirate could be used from the" exact="lower" post="respiratory tract. The BAL sample is acquired using a"/>
  <result pre="(BAL) and tracheal aspirate could be used from the lower" exact="respiratory" post="tract. The BAL sample is acquired using a bronchoscope"/>
  <result pre="used from the lower respiratory tract. The BAL sample is" exact="acquired" post="using a bronchoscope or catheter into the bronchus, where"/>
  <result pre="to collect their sputum as the sample to detect the" exact="viral infection." post="The patients will be asked to rinse the mouth"/>
  <result pre="stool, these specimens can be collected in addition to the" exact="respiratory" post="specimens. However, the efficacy of these tests remains unclear,"/>
  <result pre="efficacy of these tests remains unclear, because the data on" exact="viral" post="shedding is still preliminary. In addition, for patients who"/>
  <result pre="will be carried out to verify the presence of the" exact="viral infection." post="AN UPDATE ON DIAGNOSIS FOR COVID-19 With the number"/>
  <result pre="UPDATE ON DIAGNOSIS FOR COVID-19 With the number of COVID-19" exact="infections" post="flying off the charts, accurate and rapid diagnosis has"/>
  <result pre="approved by the WHO, which has recommended the collection of" exact="upper" post="respiratory specimens using NP swabs. If unavailable, the CDC"/>
  <result pre="by the WHO, which has recommended the collection of upper" exact="respiratory" post="specimens using NP swabs. If unavailable, the CDC and"/>
  <result pre="can be used. However, the use of this test is" exact="limited" post="to authorized laboratories alone. This test identifies the IgM"/>
  <result pre="IgG antibodies produced by the patient in response to SARS-CoV-2" exact="infection" post="(9). Likewise, ICMR has also issued some guidelines for"/>
  <result pre="Moreover, the tests available predominantly check for the presence of" exact="viral" post="nucleic acid in the specimen through RT-PCR. In order"/>
  <result pre="SARS-CoV-2 must be confirmed by sequencing of the genome. Various" exact="viral" post="proteins like orf1ab, N, RdRp, S, E, ORF1b, and"/>
  <result pre="successfully identify and contain the virus. BLOOD PROFILING IN COVID-19" exact="Blood" post="profiles and biochemical assays are the most commonly recommended"/>
  <result pre="most commonly recommended test by physicians in case of any" exact="disease" post="conditions (Supplementary Table 1). Various blood and biochemical abnormalities"/>
  <result pre="include abnormal procalcitonin, and albumin and liver enzyme levels. On" exact="viral" post="entry into the body, the virus attacks the throat,"/>
  <result pre="cells/Î¼L). This is a common sign of inflammation induced by" exact="viral" post="entry. Similarly, leukopenia is the anomalous decrease of WBCs"/>
  <result pre="a common sign of inflammation induced by viral entry. Similarly," exact="leukopenia" post="is the anomalous decrease of WBCs (less than 4,000"/>
  <result pre="cells/Î¼L) in the blood and can also result from various" exact="viral" post="infections in which the WBCs are used more quickly"/>
  <result pre="in the blood and can also result from various viral" exact="infections" post="in which the WBCs are used more quickly than"/>
  <result pre="patients. Lymphopenia is a factor that is positively correlated with" exact="disease" post="severity (14) and may be caused by the surge"/>
  <result pre="processes increase the levels of procalcitonin in the blood upon" exact="infection" post="or injury. This is concomitant with increased levels of"/>
  <result pre="like Remidesivir, increases the potential of the drug to reduce" exact="viral infection" post="(16). The Lopinavir/Ritonavir drug is currently provided to treat"/>
  <result pre="Remidesivir, increases the potential of the drug to reduce viral" exact="infection" post="(16). The Lopinavir/Ritonavir drug is currently provided to treat"/>
  <result pre="infection (16). The Lopinavir/Ritonavir drug is currently provided to treat" exact="HIV infection;" post="from the laboratory experiments, it is evident that these"/>
  <result pre="the (15), the interferon beta-1a, which is used to treat" exact="multiple sclerosis," post="can also be used as a remedial approach for"/>
  <result pre="1940s, as an aminoquinolone derivative developed for the treatment of" exact="malaria" post="(17). The chemical formula of chloroquine is C18H6CIN3. Chloroquine"/>
  <result pre="derivative, hydroxychloroquine, are very closely related and used to treat" exact="malaria" post="and rheumatologic conditions, respectively. Hydroxychloroquine is a disease-modifying anti-rheumatic"/>
  <result pre="immune system, which may be overactive in some conditions including" exact="rheumatoid arthritis," post="discoid and systemic lupus erythematosus, and juvenile idiopathic arthritis."/>
  <result pre="be overactive in some conditions including rheumatoid arthritis, discoid and" exact="systemic" post="lupus erythematosus, and juvenile idiopathic arthritis. Chloroquine and hydroxychloroquine"/>
  <result pre="overactive in some conditions including rheumatoid arthritis, discoid and systemic" exact="lupus erythematosus," post="and juvenile idiopathic arthritis. Chloroquine and hydroxychloroquine have been"/>
  <result pre="conditions including rheumatoid arthritis, discoid and systemic lupus erythematosus, and" exact="juvenile idiopathic arthritis." post="Chloroquine and hydroxychloroquine have been repurposed for the treatment"/>
  <result pre="and hydroxychloroquine have been repurposed for the treatment of several" exact="disease" post="conditions, including HIV, Systemic lupus erythematosus, and rheumatoid arthritis"/>
  <result pre="repurposed for the treatment of several disease conditions, including HIV," exact="Systemic" post="lupus erythematosus, and rheumatoid arthritis (18). Chloroquine is classified"/>
  <result pre="for the treatment of several disease conditions, including HIV, Systemic" exact="lupus erythematosus," post="and rheumatoid arthritis (18). Chloroquine is classified as an"/>
  <result pre="of several disease conditions, including HIV, Systemic lupus erythematosus, and" exact="rheumatoid arthritis" post="(18). Chloroquine is classified as an anti-malarial drug and"/>
  <result pre="several disease conditions, including HIV, Systemic lupus erythematosus, and rheumatoid" exact="arthritis" post="(18). Chloroquine is classified as an anti-malarial drug and"/>
  <result pre="anti-malarial drug and has shown potential in the treatment of" exact="avian influenza" post="A (19). Chloroquine has been indicated to treat infections"/>
  <result pre="avian influenza A (19). Chloroquine has been indicated to treat" exact="infections" post="caused by P. vivax, P. malariae, P. ovale, and"/>
  <result pre="to cleave the SARS-CoV-2 spike (S) protein and blocks the" exact="viral" post="attachment to the human host receptors. Additionally, the chloroquine"/>
  <result pre="which results in SARS-CoV-2 virus molecular crosstalk, further alters the" exact="viral" post="assembly, and intrudes into the proteolytic process of the"/>
  <result pre="functioned at both entries and post-entry stages of the 2019-nCoV" exact="infection" post="in Vero E6 cells. The in vitro study findings"/>
  <result pre="could be used to treat the patients suffering from COVID-19" exact="infection" post="(30). The patients affected with COVID-19 infection and who"/>
  <result pre="suffering from COVID-19 infection (30). The patients affected with COVID-19" exact="infection" post="and who have no complications with the chloroquine drug"/>
  <result pre="provide some indications of possible benefits of chloroquine phosphate against" exact="pneumonia" post="caused by COVID-19, but need confirmation through randomized trials"/>
  <result pre="showed 1.13 Î¼M at half-maximal concentration against SARS-CoV-2 and blocked" exact="viral infection" post="by increasing the endosomal pH required for viral fusion"/>
  <result pre="1.13 Î¼M at half-maximal concentration against SARS-CoV-2 and blocked viral" exact="infection" post="by increasing the endosomal pH required for viral fusion"/>
  <result pre="blocked viral infection by increasing the endosomal pH required for" exact="viral" post="fusion (Fig. 2) (30). Azithromycin has been suggested to"/>
  <result pre="Although a definitive treatment or specific vaccine for this deadly" exact="viral infection" post="is still a question to be answered, an experimental"/>
  <result pre="a definitive treatment or specific vaccine for this deadly viral" exact="infection" post="is still a question to be answered, an experimental"/>
  <result pre="a common adaptive immunotherapy, where the patients recovered from a" exact="viral" post="disease with high neutralising antibody titer against the virus"/>
  <result pre="common adaptive immunotherapy, where the patients recovered from a viral" exact="disease" post="with high neutralising antibody titer against the virus and"/>
  <result pre="identified intruders (SARS-CoV-2), which leads to the deactivation of the" exact="viral infection." post="The CP therapy has been used to treat several"/>
  <result pre="infection. The CP therapy has been used to treat several" exact="infectious diseases," post="including Spanish flu (1917-1918) (32), the Ebola epidemic in"/>
  <result pre="(34), influenza A (H1N1) and A(H5N1) (35). During the H1N1" exact="viral infection," post="the CP therapy gave positive results, where the respiratory"/>
  <result pre="viral infection, the CP therapy gave positive results, where the" exact="respiratory" post="tract viral load, serum cytokine levels, and mortality levels"/>
  <result pre="the CP therapy gave positive results, where the respiratory tract" exact="viral" post="load, serum cytokine levels, and mortality levels were significantly"/>
  <result pre="against the SARS-CoV-2 would be injected, which could neutralise the" exact="viral" post="load in the severely affected COVID-19 patients. For this"/>
  <result pre="researchers found that CP therapy could rescue COVID-19 patients from" exact="disease" post="severity. During this experimental assay, one dose of 200"/>
  <result pre="ml CP transfusion was readily accepted, which also reduced several" exact="symptomatic" post="conditions of the COVID-19 patients. The researchers found that"/>
  <result pre="guidelines which could help to speed up the process of" exact="viral" post="deactivation and production of the vaccine. Also, these recommendations"/>
  <result pre="the virus is still ongoing and the impact of the" exact="infection" post="is still on the rise, despite the various preventive"/>
  <result pre="precautionary measures will yield the desired result of containing this" exact="viral infection." post="We should co-operate with the health-care officials if they"/>
  <result pre="them with the desired specimens to confirm the presence or" exact="absence of" post="the infection in a particular individual. Based on the"/>
  <result pre="desired specimens to confirm the presence or absence of the" exact="infection" post="in a particular individual. Based on the efficiency of"/>
  <result pre="on convalescent plasma therapy as a remedial approach for this" exact="viral infection." post="The recovered patients should come forward to provide their"/>
  <result pre="strictly followed, as it will be easy to combat the" exact="disease" post="more expediently. People who are infected or may have"/>
  <result pre="professionals and should reduce their intake of smoking and alcohol" exact="consumption" post="in order to improve will improve their immunity. These"/>
  <result pre="be avoided, because it could increase the spread of the" exact="viral" post="load among societies. It is evident that the spread"/>
  <result pre="load among societies. It is evident that the spread of" exact="infection" post="is mainly through human-to-human transmission; hence it is mandatory"/>
  <result pre="symptom associated with this disease. Containing the spread of SARS-CoV-2" exact="infection" post="will potentially reduce the stress and strain on the"/>
  <result pre="currently it has emerged as the most intense and petrifying" exact="viral infection" post="to be handled by the human race. Many countries"/>
  <result pre="it has emerged as the most intense and petrifying viral" exact="infection" post="to be handled by the human race. Many countries"/>
  <result pre="working rigorously to find the solution to treat the SARS-CoV-2" exact="infection" post="at a rapid pace. Hence, more research is needed"/>
  <result pre="2020 2BalachandarVKaavyaJMahalaxmiIet al.2020COVID-19: A promising cure for the global panicSci" exact="Total" post="Environ[Online ahead of print]10.1016/j.scitotenv.2020.13827732278175 3ZhengFTangWLiHHuangYXieYZhouZ2020Clinical characteristics of 161 cases"/>
  <result pre="of print]10.1016/j.scitotenv.2020.13827732278175 3ZhengFTangWLiHHuangYXieYZhouZ2020Clinical characteristics of 161 cases of corona virus" exact="disease" post="2019 (COVID-19) in ChangshaEur Rev Med Pharmacol Sci243404341010.26355/eurrev_202003_2071132271459 4BalachandarVMahalaxmiIKaavyaJet"/>
  <result pre="Emerging protective measuresEur Rev Med Pharmaco243422342510.26355/eurrev_202003_2071332271461 5RotheCSchunkMSothmannPet al.2020Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN Engl J Med38297097110.1056/NEJMc200146832003551"/>
  <result pre="with 2019 novel coronavirus in Wuhan, ChinaLancet39549750610.1016/S0140-6736(20)30183-531986264 8collab: Centers for" exact="Disease" post="Prevention and Control (CDC)2020Interim guidelines for collecting, handling, and"/>
  <result pre="collecting, handling, and testing clinical specimens from persons for coronavirus" exact="disease" post="2019 (COVID-19)https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.htmlaccessed on 16 April, 2020 9collab: World Health"/>
  <result pre="(ICMR)2020https://icmr.nic.in/sites/default/files/upload_documents/Validation_of_Commercial_Kits_02042020.pdfaccessed on 16 April, 2020 11collab: World Health Organization (WHO)2020Coronavirus" exact="disease" post="(COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humanshttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical"/>
  <result pre="print]10.1002/jmv.2582232242947 13ZhouFYuTDuRet al.2020Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="features and short-term outcomes of 102 patients with corona virus" exact="disease" post="2019 in Wuhan, ChinaClin Infect Dis[Online ahead of print]10.1093/cid/ciaa24332239127"/>
  <result pre="and Research Information on Drug-Induced liver injury [Internet]National Institute of" exact="Diabetes" post="and Digestive and Kidney DiseasesBethesda (MD)2017 Feb 2 18PlantoneDKoudriavtsevaT2018Current"/>
  <result pre="Drug-Induced liver injury [Internet]National Institute of Diabetes and Digestive and" exact="Kidney" post="DiseasesBethesda (MD)2017 Feb 2 18PlantoneDKoudriavtsevaT2018Current and future use of"/>
  <result pre="Investig3865367110.1007/s40261-018-0656-y29737455 19YanYZouZSunYet al.2013Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res2330030210.1038/cr.2012.16523208422"/>
  <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res2330030210.1038/cr.2012.16523208422 20LiCZhuXJiXet al.2017Chloroquine, a FDA-approved"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res2330030210.1038/cr.2012.16523208422 20LiCZhuXJiXet al.2017Chloroquine, a FDA-approved"/>
  <result pre="animal modelCell Res2330030210.1038/cr.2012.16523208422 20LiCZhuXJiXet al.2017Chloroquine, a FDA-approved drug, prevents Zika" exact="virus infection" post="and its associated congenital microcephaly in miceEBioMedicine2418919410.1016/j.ebiom.2017.09.03429033372 21ShiryaevSAMesciPPintoAet al.2017Repurposing"/>
  <result pre="modelCell Res2330030210.1038/cr.2012.16523208422 20LiCZhuXJiXet al.2017Chloroquine, a FDA-approved drug, prevents Zika virus" exact="infection" post="and its associated congenital microcephaly in miceEBioMedicine2418919410.1016/j.ebiom.2017.09.03429033372 21ShiryaevSAMesciPPintoAet al.2017Repurposing"/>
  <result pre="a FDA-approved drug, prevents Zika virus infection and its associated" exact="congenital" post="microcephaly in miceEBioMedicine2418919410.1016/j.ebiom.2017.09.03429033372 21ShiryaevSAMesciPPintoAet al.2017Repurposing of the anti-malaria drug"/>
  <result pre="FDA-approved drug, prevents Zika virus infection and its associated congenital" exact="microcephaly" post="in miceEBioMedicine2418919410.1016/j.ebiom.2017.09.03429033372 21ShiryaevSAMesciPPintoAet al.2017Repurposing of the anti-malaria drug chloroquine"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis[Online ahead of"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis[Online ahead of print]10.1093/cid/ciaa23732150618"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis[Online ahead of print]10.1093/cid/ciaa23732150618 23GaoJTianZYangX2020Breakthrough:"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends14727310.5582/bst.2020.0104732074550 24SavarinoADi TraniLDonatelliICaudaRCassoneA2006New insights into the"/>
  <result pre="Res3026927110.1038/s41422-020-0282-032020029 27VincentMJBergeronEBenjannetSet al.2005Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J26910.1186/1743-422X-2-6916115318 28DevauxCARolainJMColsonPRaoultD2020New insights on the antiviral effects"/>
  <result pre="J Antimicrob Agents[Online ahead of print]10.1016/j.ijantimicag.2020.10593832171740 29SavarinoABoelaertJRCassoneAMajoriGCaudaR2003Effectd of chloroquine on" exact="viral" post="infections: an old drug against today's diseasesLancet Infect Dis372272710.1016/S1473-3099(03)00806-514592603"/>
  <result pre="33Van GriensvenJEdwardsTde LamballerieXet al.2016Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in GuineaN Engl J Med374334210.1056/NEJMoa151181226735992 34ZhouBZhongNGuanY2007Treatment with convalescent plasma"/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis211809010.1093/infdis/jiu39625030060"/>
  <result pre="(H1N1) 2009 virus infectionClin Infect Dis5244745610.1093/cid/ciq10621248066 37ChengZLuYCaoQet al.2020Clinical features and" exact="chest" post="CT manifestations of coronavirus disease 2019 (COVID-19) in a"/>
  <result pre="Dis5244745610.1093/cid/ciq10621248066 37ChengZLuYCaoQet al.2020Clinical features and chest CT manifestations of coronavirus" exact="disease" post="2019 (COVID-19) in a single-center study in Shanghai, ChinaAm"/>
  <result pre="38KoJHSeokHChoSYet al.2018Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: a single centre experienceAntivir ther2361762210.3851/IMP324329923831 39LeePIHsuehPR2020Emerging threats"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov61610.1038/s41421-020-0156-032194981 Fig. 1 Collection of Specimens/samples and"/>
  <result pre="to a laboratory. Here, RT-PCR analysis is conducted using specific" exact="viral" post="gene probes targeting viral specific genes. If the viral"/>
  <result pre="RT-PCR analysis is conducted using specific viral gene probes targeting" exact="viral" post="specific genes. If the viral nucleic acid is present"/>
  <result pre="specific viral gene probes targeting viral specific genes. If the" exact="viral" post="nucleic acid is present in the specimens, the patients"/>
  <result pre="the SARS-CoV-2 spike (S1 and S2) protein and blocks the" exact="viral" post="attachment to the human host receptors. (3) The drug"/>
  <result pre="of the cellular receptors of SARS-CoV-2, which eventually blocks the" exact="viral" post="attachment to the ACE2 receptors and inhibits the viral"/>
  <result pre="the viral attachment to the ACE2 receptors and inhibits the" exact="viral infection." post="(4) Moreover, the hydroxychloroquine obstructs the MAP-kinase pathway which"/>
  <result pre="results to SARS-CoV-2 virus molecular crosstalk resulting into alteration of" exact="viral" post="assembly and also intrude the proteolytic process of the"/>
  <result pre="blood cells to identify the SARS-CoV-2 virus which deactivates the" exact="viral" post="function in the human body. In this procedure almost"/>
  <result pre="to the COVID-19 diseased patients. This might reduce the COVID-19" exact="disease" post="symptoms, give relief to the patients and would get"/>
  <result pre="Form of sample collection Volume Required Collection Material Storage Temperature" exact="Disease" post="Condition Test can be done Nasopharyngeal Swab Frozen 0.8-1.4"/>
  <result pre="Synthetic fibre swabs with plastic shafts 2-8Â°C Recommended for both" exact="symptomatic" post="and asymptomatic RT-PCR RDT Oropharyngeal Swab Frozen 0.8-1.4 ml"/>
  <result pre="RT-PCR RDT Bronchoalveolar lavage Frozen 0.8-1.4 ml Sterile Container 2-8Â°C" exact="Severe" post="Condition RT-PCR RDT Tracheal aspirate Frozen 0.8-1.4 ml Sterile"/>
  <result pre="RT-PCR RDT Tracheal aspirate Frozen 0.8-1.4 ml Sterile Container 2-8Â°C" exact="Severe" post="Condition RT-PCR RDT Sputum Frozen 0.8-1.4 ml Sputum collection"/>
  <result pre="0.8-1.4 ml Sputum collection cup or sterile dry container 2-8Â°C" exact="Severe" post="Condition RT-PCR RDT Urine Normal 0.8-1.4 ml Urine collection"/>
  <result pre="or sterile dry container 2-8Â°C Severe Condition RT-PCR RDT Urine" exact="Normal" post="0.8-1.4 ml Urine collection container 2-8Â°C To confirm the"/>
  <result pre="Normal 0.8-1.4 ml Urine collection container 2-8Â°C To confirm the" exact="viral infection" post="RT-PCR Blood Normal 0.8-1.4 ml EDTA &amp;amp; ACT tubes"/>
  <result pre="0.8-1.4 ml Urine collection container 2-8Â°C To confirm the viral" exact="infection" post="RT-PCR Blood Normal 0.8-1.4 ml EDTA &amp;amp; ACT tubes"/>
  <result pre="Urine collection container 2-8Â°C To confirm the viral infection RT-PCR" exact="Blood" post="Normal 0.8-1.4 ml EDTA &amp;amp; ACT tubes 2-8Â°C To"/>
  <result pre="collection container 2-8Â°C To confirm the viral infection RT-PCR Blood" exact="Normal" post="0.8-1.4 ml EDTA &amp;amp; ACT tubes 2-8Â°C To confirm"/>
  <result pre="0.8-1.4 ml EDTA &amp;amp; ACT tubes 2-8Â°C To confirm the" exact="viral infection" post="RT-PCR RDT ELISA Neutralization assay Stool Normal - Stool"/>
  <result pre="ml EDTA &amp;amp; ACT tubes 2-8Â°C To confirm the viral" exact="infection" post="RT-PCR RDT ELISA Neutralization assay Stool Normal - Stool"/>
  <result pre="confirm the viral infection RT-PCR RDT ELISA Neutralization assay Stool" exact="Normal" post="- Stool container 2-8Â°C To confirm the viral infection"/>
  <result pre="assay Stool Normal - Stool container 2-8Â°C To confirm the" exact="viral infection" post="RT-PCR RT-PCR: Reverse Transcription-Polymerase Chain Reaction; RDT: Rapid Diagnostic"/>
  <result pre="Stool Normal - Stool container 2-8Â°C To confirm the viral" exact="infection" post="RT-PCR RT-PCR: Reverse Transcription-Polymerase Chain Reaction; RDT: Rapid Diagnostic"/>
  <result pre="Antiviral Activity of Remdesivir (GS-5734TM) in Participants with Moderate Coronavirus" exact="Disease" post="(COVID-19) Compared to Standard of Care Treatment Remdesivir Recruiting"/>
  <result pre="of Health - Clinical left, National Institute of Allergy and" exact="Infectious" post="Diseases Laboratory of Immunoregulation, Clinical Research SectionBethesda, Maryland, United"/>
  <result pre="Health - Clinical left, National Institute of Allergy and Infectious" exact="Diseases" post="Laboratory of Immunoregulation, Clinical Research SectionBethesda, Maryland, United States"/>
  <result pre="Maryland, United States 2. University of Nebraska Medical left -" exact="Infectious" post="DiseasesOmaha, Nebraska, United States 3. University of Texas Medical"/>
  <result pre="States 3. University of Texas Medical Branch - Division of" exact="Infectious" post="DiseaseGalveston, Texas, United States 4. Providence Sacred Heart Medical"/>
  <result pre="Division of Infectious DiseaseGalveston, Texas, United States 4. Providence Sacred" exact="Heart" post="Medical leftSpokane, Washington, United States Ongoing Clinical Trials for"/>
  <result pre="Thymosin; suramin; conventional treatment + adalimumab Not yet recruiting China" exact="Severe" post="2019-nCoV Remdesivir RCT Remdesivir Recruiting Bin Cao; Beijing, Beijing,"/>
  <result pre="Bin Cao; Beijing, Beijing, China Nitric Oxide Gas Inhalation for" exact="Severe" post="Acute Respiratory Syndrome in COVID-19 Nitric Oxide Gas Not"/>
  <result pre="Cao; Beijing, Beijing, China Nitric Oxide Gas Inhalation for Severe" exact="Acute" post="Respiratory Syndrome in COVID-19 Nitric Oxide Gas Not yet"/>
  <result pre="Beijing, Beijing, China Nitric Oxide Gas Inhalation for Severe Acute" exact="Respiratory" post="Syndrome in COVID-19 Nitric Oxide Gas Not yet recruiting"/>
  <result pre="Beijing, China Nitric Oxide Gas Inhalation for Severe Acute Respiratory" exact="Syndrome" post="in COVID-19 Nitric Oxide Gas Not yet recruiting -"/>
  <result pre="Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus" exact="Infection" post="1. ASC09/ritonavir group Not yet recruiting - 2. Lopinavir/ritonavir"/>
  <result pre="and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2" exact="Infection" post="mRNA-1273 Not yet recruiting Kaiser Permanente Washington Health Research"/>
  <result pre="recruiting Kaiser Permanente Washington Health Research Institute - Vaccines and" exact="Infectious" post="DiseasesSeattle, Washington, United States Study to Evaluate the Safety"/>
  <result pre="Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With" exact="Severe" post="Coronavirus Disease (COVID-19) Remdesivir Recruiting 1. Hoag Memorial Hospital"/>
  <result pre="Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Severe Coronavirus" exact="Disease" post="(COVID-19) Remdesivir Recruiting 1. Hoag Memorial Hospital PresbyterianNewport Beach,"/>
  <result pre="University Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients with" exact="Severe" post="Acute Respiratory Failure Methylprednisolone Recruiting Medical ICU,Peking Union Medical"/>
  <result pre="Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients with Severe" exact="Acute" post="Respiratory Failure Methylprednisolone Recruiting Medical ICU,Peking Union Medical College"/>
  <result pre="Therapy for Novel Coronavirus Critically Ill Patients with Severe Acute" exact="Respiratory" post="Failure Methylprednisolone Recruiting Medical ICU,Peking Union Medical College HospitalBeijing,"/>
  <result pre="for Novel Coronavirus Critically Ill Patients with Severe Acute Respiratory" exact="Failure" post="Methylprednisolone Recruiting Medical ICU,Peking Union Medical College HospitalBeijing, Beijing,"/>
  <result pre="and safety of carrimycin treatment in patients with novel coronavirus" exact="infectious disease" post="(COVID-19): a multileft, randomized, open- label controlled trial Carrimycin"/>
  <result pre="safety of carrimycin treatment in patients with novel coronavirus infectious" exact="disease" post="(COVID-19): a multileft, randomized, open- label controlled trial Carrimycin"/>
  <result pre="alpha 1b spray in the prevention of novel coronavirus (COVID-19)" exact="infection" post="in highly exposed medical staffs recombinant human interferon alpha"/>
  <result pre="medical staffs recombinant human interferon alpha 1b - Chinese PLA" exact="General" post="Hospital A Pilot Study of Sildenafil in COVID-19 Sildenafil"/>
  <result pre="Sildenafil in COVID-19 Sildenafil citrate Recruiting Department and Institute of" exact="Infectious" post="Disease, Wuhan, Hubei, China A study for the efficacy"/>
  <result pre="for the efficacy of hydroxychloroquine for mild and moderate COVID-19" exact="infectious diseases" post="Hydroxychloroquine - The Second Affiliated Hospital of Chongqing Medical"/>
  <result pre="of Chongqing Medical University The Efficacy and Safety of Thalidomide" exact="Combined" post="with Low-dose Hormones in the Treatment of Severe COVID-19"/>
  <result pre="of Thalidomide Combined with Low-dose Hormones in the Treatment of" exact="Severe" post="COVID-19 Thalidomide Not yet recruiting - Various Combination of"/>
  <result pre="of Minnesota, Minneapolis, Minnesota, United States Chloroquine Prevention of Coronavirus" exact="Disease" post="(COVID-19) in the Healthcare Setting Chloroquine Not yet recruiting"/>
  <result pre="in the Healthcare Setting Chloroquine Not yet recruiting - Favipiravir" exact="Combined" post="with Tocilizumab in the Treatment of Corona Virus Disease"/>
  <result pre="- Favipiravir Combined with Tocilizumab in the Treatment of Corona" exact="Virus Disease" post="2019 Favipiravir Combined with Tocilizumab Recruiting Anhui Medical University"/>
  <result pre="Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus" exact="Disease" post="2019 Favipiravir Combined with Tocilizumab Recruiting Anhui Medical University"/>
  <result pre="Tocilizumab in the Treatment of Corona Virus Disease 2019 Favipiravir" exact="Combined" post="with Tocilizumab Recruiting Anhui Medical University Affiliated First Hospital,"/>
  <result pre="Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients with Mild Coronavirus" exact="Disease" post="(COVID-19) 1. Lopinavir/ritonavir Hydroxychloroquine sulfate Recruiting Asan Medical left,"/>
  <result pre="Medicine, Seoul, Korea, Republic of Korea Evaluation of Ganovo (Danoprevir)" exact="Combined" post="with Ritonavir in the Treatment of Novel Coronavirus Infection"/>
  <result pre="(Danoprevir) Combined with Ritonavir in the Treatment of Novel Coronavirus" exact="Infection" post="Ganovo with ritonavir +/-Interferon Recruiting The Ninth Hospital of"/>
  <result pre="(Soliris) in Covid-19 Infected Patients Eculizumab Initiated - Norwegian Coronavirus" exact="Disease" post="2019 Study Hydroxychloroquine Sulfate Not yet recruiting - Post-exposure"/>
  <result pre="of pirfenidone capsules in the treatment of severe new coronavirus" exact="pneumonia" post="(COVID-19) Pirfenidone - Third Xiangya Hospital of Central South"/>
  <result pre="new coronavirus pneumonia (COVID-19) Pirfenidone - Third Xiangya Hospital of" exact="Central" post="South University Clinical characteristics of 138 hospitalized patients with"/>
  <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China Oseltamivir Recruiting Zhongnan Hospital of Wuhan"/>
  <result pre="COVID-19 Name of Drug Illnesses treated Ribavirin RSV and RSV" exact="pneumonia" post="Reverse transcriptase inhibitors: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir"/>
  <result pre="dipivoxil SARS Baricitinib COVID-19 Umifenovir ARVI, influenza, rhinovirus, adenovirus, parainfluenza," exact="respiratory" post="syncytial virus, coronavirus, including the causative agent of atypical"/>
  <result pre="parainfluenza, respiratory syncytial virus, coronavirus, including the causative agent of" exact="atypical pneumonia" post="Used in the phase III trials of 2019-nCoV virus,"/>
  <result pre="respiratory syncytial virus, coronavirus, including the causative agent of atypical" exact="pneumonia" post="Used in the phase III trials of 2019-nCoV virus,"/>
  <result pre="SARS, Human Coronavirus OC43 Chloroquine phosphate; Arbidol COVID-19 ASC09 ARDS," exact="Respiratory" post="distress syndrome, SARS, MERS TMPRSS2 inhibitor Camostat mesylate SARS,"/>
  <result pre="RNA polymerase SARS, Murine Coronavirus Tocilizumab COVID-19 Î±-interferon Spectrum of" exact="respiratory" post="infectionsÎˆ RSV and SARS Table 3 represents the commercially"/>
  <result pre="for the treatment of the various forms of coronaviruses. The" exact="viral" post="infections discussed in the table are SARS - Severe"/>
  <result pre="the treatment of the various forms of coronaviruses. The viral" exact="infections" post="discussed in the table are SARS - Severe Acute"/>
  <result pre="The viral infections discussed in the table are SARS -" exact="Severe" post="Acute Respiratory Syndrome, MERS-Middle East Respiratory Syndrome, RSV -"/>
  <result pre="viral infections discussed in the table are SARS - Severe" exact="Acute" post="Respiratory Syndrome, MERS-Middle East Respiratory Syndrome, RSV - Respiratory"/>
  <result pre="infections discussed in the table are SARS - Severe Acute" exact="Respiratory" post="Syndrome, MERS-Middle East Respiratory Syndrome, RSV - Respiratory Syncytial"/>
  <result pre="table are SARS - Severe Acute Respiratory Syndrome, MERS-Middle East" exact="Respiratory" post="Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute"/>
  <result pre="Severe Acute Respiratory Syndrome, MERS-Middle East Respiratory Syndrome, RSV -" exact="Respiratory" post="Syncytial Virus, ARVI - Acute respiratory viral infections. Table"/>
  <result pre="East Respiratory Syndrome, RSV - Respiratory Syncytial Virus, ARVI -" exact="Acute" post="respiratory viral infections. Table 4 Chloroquine and its combination"/>
  <result pre="Respiratory Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute" exact="respiratory" post="viral infections. Table 4 Chloroquine and its combination of"/>
  <result pre="Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute respiratory" exact="viral" post="infections. Table 4 Chloroquine and its combination of drugs"/>
  <result pre="COVID-19 Study Particulars Drugs Dosage Reference Chloroquine (C) phosphate against" exact="pneumonia" post="caused by COVID-19 but need confirmation through randomized trials"/>
  <result pre="randomized trials Chloroquine phosphate Not specified 15 SARS-CoV-2 and blocked" exact="viral infection" post="by increasing the endosomal pH required for viral fusion"/>
  <result pre="trials Chloroquine phosphate Not specified 15 SARS-CoV-2 and blocked viral" exact="infection" post="by increasing the endosomal pH required for viral fusion"/>
  <result pre="blocked viral infection by increasing the endosomal pH required for" exact="viral" post="fusion Chloroquine 1.13 Î¼M at half maximal concentration 27"/>
  <result pre="2020) Two drugs, remdesivir and chloroquine phosphate, efficiently inhibited SARS-CoV-2" exact="infection" post="in vitro Remdesivir + chloroquine phosphate Not specified 27"/>
  <result pre="chloroquine phosphate Not specified 27 (Nichol et al., 2020) COVID-19" exact="pneumonia" post="and without contraindications to chloroquine, be treated with 500"/>
  <result pre="against SARSâ€&quot;CoV-2 in vitro and in small, poorly controlled or" exact="uncontrolled" post="clinical studies Chloroquine and Hydroxychloroquine Not specified 22 (Zhang"/>
  <result pre="22 (Zhang et al., 2020) Reducing symptom duration, exacerbation of" exact="pneumonia" post="including radiological improvement and promoting virus-negative seroconversion without any"/>
 </snippets>
</snippetsTree>
